These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32515579)

  • 21. Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4)- and Programmed Death 1 (PD-1)-Mediated Regulation of Monofunctional and Dual Functional CD4
    Rajamanickam A; Munisankar S; Dolla C; Nutman TB; Babu S
    Infect Immun; 2019 Dec; 87(12):. PubMed ID: 31570560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineered Small Extracellular Vesicles as a FGL1/PD-L1 Dual-Targeting Delivery System for Alleviating Immune Rejection.
    Tsai HI; Wu Y; Liu X; Xu Z; Liu L; Wang C; Zhang H; Huang Y; Wang L; Zhang W; Su D; Khan FU; Zhu X; Yang R; Pang Y; Eriksson JE; Zhu H; Wang D; Jia B; Cheng F; Chen H
    Adv Sci (Weinh); 2022 Jan; 9(3):e2102634. PubMed ID: 34738731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
    Fife BT; Bluestone JA
    Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A computational study of co-inhibitory immune complex assembly at the interface between T cells and antigen presenting cells.
    Su Z; Dhusia K; Wu Y
    PLoS Comput Biol; 2021 Mar; 17(3):e1008825. PubMed ID: 33684103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
    Kassardjian A; Shintaku PI; Moatamed NA
    PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extracellular vesicle-based checkpoint regulation and immune state in cancer.
    Mortezaee K; Majidpoor J
    Med Oncol; 2022 Sep; 39(12):225. PubMed ID: 36175741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the
    Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
    Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer.
    Zhang W; Shi L; Zhao Z; Du P; Ye X; Li D; Cai Z; Han J; Cai J
    Cancer Chemother Pharmacol; 2019 May; 83(5):911-920. PubMed ID: 30848330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmed death ligand-1 induction restrains the cytotoxic T lymphocyte response against microglia.
    Chauhan P; Hu S; Prasad S; Sheng WS; Lokensgard JR
    Glia; 2021 Apr; 69(4):858-871. PubMed ID: 33128485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.
    Nishimura CD; Pulanco MC; Cui W; Lu L; Zang X
    Trends Mol Med; 2021 Mar; 27(3):207-219. PubMed ID: 33199209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD8
    Bracamonte-Baran W; Gilotra NA; Won T; Rodriguez KM; Talor MV; Oh BC; Griffin J; Wittstein I; Sharma K; Skinner J; Johns RA; Russell SD; Anders RA; Zhu Q; Halushka MK; Brandacher G; Čiháková D
    Circ Heart Fail; 2021 Oct; 14(10):e007982. PubMed ID: 34555935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis.
    Cho H; Kang H; Lee HH; Kim CW
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.
    Chang H; Jung W; Kim A; Kim HK; Kim WB; Kim JH; Kim BH
    APMIS; 2017 Aug; 125(8):690-698. PubMed ID: 28493410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
    Singh L; Singh MK; Rizvi MA; Pushker N; Bakhshi S; Sen S; Kashyap S
    Br J Ophthalmol; 2021 Jan; 105(1):48-56. PubMed ID: 32277010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
    Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint.
    Xu S; Tao Z; Hai B; Liang H; Shi Y; Wang T; Song W; Chen Y; OuYang J; Chen J; Kong F; Dong Y; Jiang SW; Li W; Wang P; Yuan Z; Wan X; Wang C; Li W; Zhang X; Chen K
    Nat Commun; 2016 May; 7():11406. PubMed ID: 27147225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours.
    Ariyarathna H; Thomson NA; Aberdein D; Perrott MR; Munday JS
    Vet Immunol Immunopathol; 2020 Dec; 230():110142. PubMed ID: 33129194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 are Blocked by
    Li W; Kim TI; Kim JH; Chung HS
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31717574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineering Cell Membrane-Based Nanovesicles for Melanoma Tumor Treatment.
    Xin S; Wu Y; Huang Z; Huang Y; Jia B; Zhao J
    J Biomed Nanotechnol; 2021 May; 17(5):838-845. PubMed ID: 34082870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.